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We assessed hepatitis E virus (HEV) antibody 
seroprevalence in a sample of the adult population in 
Germany. Overall HEV IgG prevalence was 16.8% (95% CI 
15.6%–17.9%) and increased with age, leveling off at >60 
years of age. HEV is endemic in Germany, and the lifetime 
risk for exposure is high.
In industrialized countries, hepatitis E virus (HEV) has long been regarded as a rare imported infection. 
However, sporadic cases without travel to disease-endemic 
areas and caused by genotype 3 are being increasingly 
reported (1,2). Epidemiologic and molecular studies have 
implicated undercooked pork and wild boar products as 
a source of HEV infection (3–5). An unexpectedly high 
prevalence of HEV-specifi c antibodies, e.g., among blood 
donors, has been shown by several studies in Europe and 
the United States (6–11).
In Germany, the number of notifi ed hepatitis E cases 
rose from <50 annually in 2001–2003 to 238 in 2011 
(incidence 0.3/100,000 population); the proportion of 
autochthonous cases increased from 30%–40% to 78%. 
We conducted a study to determine HEV seroprevalence 
in Germany’s adult population and associations with 
sociodemographic characteristics by using an assay highly 
sensitive for HEV genotype 3.
The Study
We assessed HEV seroprevalence in a large 
subsample (n = 4,422) of the 2008–2011 German Health 
Examination Survey for Adults (Deutscher Erwachsenen 
Gesundheitssurvey; www.degs-studie.de), a 2-stage 
national probability sample that assessed the health status 
in the general population. The sampling frame comprised 
persons 18–79 years of age whose principal residence 
was in Germany and who were fl uent in German. Overall 
response was 48.4% (7,116 respondents). Our subsample 
refl ects the total adult population with respect to age, 
sex, and geographic region, but persons with migration 
background are underrepresented (non-German citizenship 
4.6% in the sample vs. 8.7% in the total adult population).
Serum samples were screened for HEV IgG by using 
the recomLine HEV-IgG/IgM immunoassay (Mikrogen, 
Neuried, Germany). The assay is based on 7 recombinantly 
expressed antigens of genotypes 1 and 3 of open reading 
frames 2 and 3. According to the manufacturer’s and our 
data (J.J. Wenzel et al., unpub. data), the test is 97%–100% 
sensitive for detecting acute or previous HEV infections. 
Test strips were scanned with the semiautomatic recomScan 
software (Mikrogen). The intensity of 3 quality assurance 
and other bands was determined by densitometrical 
detection algorithms. Each antigen band with an intensity 
greater or equal to the cutoff was assigned a point value. The 
fi nal results were classifi ed into 3 categories: no antibodies 
detectable (negative), test inconclusive (borderline), and 
antibodies detectable (positive). Persons whose test results 
were borderline (n = 70) were excluded from further 
analysis. 
We poststratifi ed the remaining survey population 
(n = 4,352) by age group and location of residence 
(16 states) to account for per protocol oversampling in 
eastern Germany and to restore the distribution of age 
groups to match the distribution in the total population. 
Weighted seroprevalence estimates were calculated by 
using survey-weighted logistic regression. Associations 
between demographic characteristics and seropositivity 
were analyzed by using adjusted Wald test p values. 
We also estimated mean annual incidence of HEV 
seroconversion from the seroprevalence data by using 
a catalytic model with age-constant force of infection, 
similar to that of Faramawi et al. (12). Detailed methods 
and underlying assumptions are described in the online 
Technical Appendix (wwwnc.cdc.gov/EID/pdfs/11-1756-
Techapp.pdf).
The 4,352 persons who were included in the analysis 
were from 108 communities of all federal states in 
Germany (Table 1). Weighted prevalence of HEV IgG was 
16.8% (95% CI 15.6%–17.9%); prevalence ranged from 
6.1% (95% CI 4.5%–7.8%) in the 18–34-year age group to 
>20% in the >50-year groups, with a maximum of 26.4% 
(95% CI 21.6%–31.1%) in the 60–64-year group (Figure). 
In the univariable analysis (Table 2), only age group was 
signifi cantly associated with seropositivity (p<0.01); results 
were not signifi cant for sex (p = 0.97), residence (northern/
middle/southern Germany, p = 0.29; west/east, p = 0.43), 
or population of municipality (4 categories; p = 0.10). In 
separate multivariable models, each including age group 
and 1 other variable, age remained the only signifi cant 
DISPATCHES
1654 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 18, No. 10, October 2012
1These authors contributed equally to this article.
Author affi liations: Robert Koch Institute, Berlin, Germany 
(M.S. Faber, M. Thamm, M. Höhle, K. Stark); and University of 
Regensburg, Regensburg, Germany (J.J. Wenzel, W. Jilg)
DOI: http://dx.doi.org/10.3201/eid1810.111756
Hepatitis E Virus Seroprevalence, Germany
variable. Mean annual incidence of HEV seroconversion 
estimated from the catalytic model was 3.9 (95% CI 3.6%–
4.2%) per 1,000 population.
Conclusions
We found an overall HEV seroprevalence of 16.8% 
among adults in Germany; seroprevalence increased with 
age but was not dependent on sex or location of residence. 
Similarly high seroprevalence was found in blood donors 
in Denmark (20.6%), southwestern England (16%), and the 
United States (18%) (6,7,9). Estimates from Switzerland 
and the Netherlands, on the other hand, are considerably 
lower (10,11). Reasons for these differences could be 
effects of sample selection, different lifetime exposures 
(e.g., to foods that may serve as transmission vehicles), 
or use of different test systems with varying sensitivity. 
Mansuy et al. recently reported 53% prevalence of HEV 
antibodies in blood donors in southwestern France (13), 
a fi gure considerably higher than the 17% prevalence 
reported earlier for the same geographic region, when a 
different test system was used (8). The assay applied in our 
study was designed to also detect previous infections with 
HEV genotype 3; therefore, it is likely to be more sensitive 
than assays used in previous studies.
Our data show that HEV exposure is common among 
the general adult population in Germany, which is consistent 
with increasing evidence for pigs as a reservoir for 
foodborne transmission of HEV in industrialized countries. 
HEV seroprevalence is high in domestic pig herds in 
Germany and other countries; closely related HEV strains 
were found in pig livers on retail sale and in autochthonous 
cases of hepatitis E, and HEV seroprevalence was higher in 
persons with occupational exposure to pigs than in control 
groups (4,10,14,15). 
Our data and other studies (11–14) have shown no 
signifi cant difference in seroprevalence between sexes, 
despite an assumed higher frequency of alimentary or 
occupational exposure and the higher incidence of clinical 
cases among men. This fi nding may indicate sex-specifi c 
differences in disease development or application of 
laboratory testing or that foods frequently consumed by both 
sexes play a substantial role as vehicles for transmission. 
These results also may highlight the lack of evidence for 1 
main risk factor or food vehicle (14). 
The strong association between age and HEV 
seroprevalence in our study most likely refl ects 
cumulative lifetime exposure to the virus. However, HEV 
seroprevalence remains relatively stable from 18 to 34 
years of age, which could indicate a birth cohort effect 
resulting from a decrease in the overall risk over the past 
few decades, as was reported for Denmark (6). The leveling 
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Table 1. Comparison of demographic characteristics of persons 
in study of hepatitis E virus seroprevalence and general adult 






population, n = 
64,139,871* 
Age group, y   
 18–19 3.2 2.9 
 20–29 12.3 15.5 
 30–39 11.5 15.6 
 40–49 18.4 21.7 
 50–59 19.5 17.9 
 60–69 19.7 14.3 
 70–79 15.4 12.2 
Female sex 51.3 50.3 
State of residence   
 Baden-Württemberg 11.4 13.0 
 Bavaria 10.7 15.2 
 Berlin 3.4 4.4 
 Brandenburg 6.2 3.2 
 Bremen 0.9 0.8 
 Hamburg 1.4 2.2 
 Hesse 6.4 7.4 
 Mecklenburg-Vorpommern 3.8 2.1 
 Lower Saxony 11.2 9.5 
 North Rhine-Westphalia 14.8 21.6 
 Rhineland-Palatinate 5.1 4.8 
 Saarland 2.2 1.3 
 Saxony 7.1 5.3 
 Saxony-Anhalt 6.2 3.0 
 Schleswig-Holstein 2.6 3.4 
 Thuringia 6.7 2.9 
*Total no. adults 18–79 years of age as of December 31, 2009 
(www.destatis.de). 
Figure. Estimated prevalence 
of hepatitis E virus (HEV) IgG, 
by age group, Germany, 2008–
2011. Error bars indicate 95% 
CIs.
off of the seroprevalence above age 60 years could be 
caused by a loss of antibodies in the elderly.
We found a striking difference between the estimated 
annual incidence of seroconversion and the relatively 
low incidence of notifi ed disease in Germany. Besides 
underdiagnosis, a possible explanation is a high proportion 
of asymptomatic infections.
The survey response rate is similar to those achieved in 
other comprehensive national health examination surveys 
in Europe. In the statistical analysis, we corrected for 
differences in the distribution of age and place of residence 
between the sample and the general population. However, 
foreign-born persons are underrepresented in the survey 
because participation required fl uency in German. A 
high proportion of foreign-born persons in Germany are 
Muslim, and their avoidance of raw pork products likely 
decreases their risk for HEV infection, which means we 
may have slightly overestimated the seroprevalence in the 
adult general population.
Autochthonous HEV infections are common in the 
industrialized world, and testing for HEV is indicated in 
patients with acute hepatitis, irrespective of history of 
travel to developing countries. Recommendations against 
eating undercooked pork products exist, but further studies 
are needed to specify implicated food products and to 
better target recommendations for safer food production, 
preparation, and consumption.
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Table 2. Univariable survey-weighted logistic regression 
estimates of seroprevalence of hepatitis E virus IgG, by age, sex, 




Total 16.8 (15.6–17.9) 
Age group, y  
 18–19 5.3 (2.5–11.1) 
 20–29 6.6 (4.8–9.2) 
 30–39 8.0 (5.8–10.8) 
 40–49 16.9 (14.3–19.9) 
 50–59 22.6 (19.7–25.7) 
 60–69 26.1 (23.0–29.4) 
 70–79 23.8 (20.4–27.5) 
Sex
 M 16.8 (15.2–18.5) 
 F 16.7 (15.2–18.5) 
Place of residence (north–south)  
 Northern states 15.5 (13.5–17.6) 
 Middle states 16.6 (14.8–18.6) 
 Southern states 17.9 (15.8–20.1) 
Place of residence (east-west)  
 Western states 16.6 (15.2–18.0) 
 Eastern states 17.6 (15.6–19.7) 
Population of municipality  
 <5,000 17.9 (15.3–20.8) 
 5,000–<20,000 17.5 (15.2–20.1) 
 20,000–<100,000 14.4 (12.4–16.6) 
 >100,000 17.7 (15.7–20.0) 
*n = 4,352. 
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